Jemperli (dostarlimab)

Numéro de dossier de l’APP: 21991
État des négociations:
Negotiations were not pursued
Indication(s):
For the treatment of adult patients mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum containing regimen
Promoteur/fabricant:
GlaxoSmithKline Inc.
Numéro de projet de l’ACMTS:
PC0263
Lettre-contrat de l’APP:
Not Applicable
Conclusion du processus de négociation: